4/1/2026 Letter on Hemp-Derived Cannabidiol Products in Medical Research Models (PDF – 212 KB) 2/24/2025 Product Resolution of Tirzepatide Injection Shortage and Supply Status (PDF – 1.103 KB) 5/21/2024 Drug Approval Package: JAYPIRCA 11/9/2023 First Interchangeable Exclusivity Expiration Memorandum for Cyltezo October 3, 2023 (PDF – 1.41MB) 5/15/2023 Adverse event report for Syfovre (PDF – 126KB) 5/19/2022 Epidemiology Review: Consumer Opioid Disposal Literature Scan and Search Results (dated April 29, 2021) (PDF – 569KB) 7/31/2020 FDA Letter to USP: Reporting Threshold in USP-NF Monographs 6/30/2020 COVID-19 Related Records 5/20/2020 Exclusivity Summary for Testosterone undecanoate (oral) (dated August 6, 2019) (PDF – 110KB) 5/20/2020 Exclusivity Summary for Testosterone undecanoate (oral) (dated March 27, 2019) (PDF – 50KB) 8/5/2019 Additional Information on Transmucosal Immediate Release Fentanyl (TIRF) REMS 2/25/2019 Additional Information on Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics REMS 5/3/2019 Decision to waive the requirement for a single, shared system REMS program for ambrisentan tablet products (dated March 22, 2019) (PDF – 61KB) 2/25/2019 TIRF FDA Memo on REMS Modification (10-31-2013) (PDF – 166KB) 2/25/2019 TIRF FDA Memo on REMS Modification (6-1-2012) (PDF – 91KB) 2/25/2019 ERLA Six-Month Assessment Report (PDF – 2.91MB) 9/26/2018 Adverse Event Reports for Pharmacovigilance Review of INSTIs and NTDs plus Spinal Malformations 6-13-18 (PDF – 1.16MB) 9/26/2018 Pharmacovigilance Review of INSTIs and NTDs plus Spinal Malformations 6-13-18 (PDF – 1.57MB) 3/28/2018 FDA Letter to USP: Drug Product Monographs for Biological Products (PDF – 609KB) 3/6/2018 Kratom additional death adverse event reports (PDF – 1MB) 2/9/2018 Decision to waive the requirement for a single, shared system REMS program for alosetron hydrochloride products (dated April 30, 2015) (PDF – 277KB) 2/6/2018 Adverse event reports regarding Kratom that resulted in death (PDF – 7MB) 8/31/2017 Additional Information NDA 206488 Exondys 51 (eteplirsen) Approval 3/27/2017 Teething Tablet Adverse Event Reports Part 1 of 3 (PDF – 57MB) 3/27/2017 Teething Tablet Adverse Event Reports Part 2 of 3 (PDF – 89MB) 3/27/2017 Teething Tablet Adverse Event Reports Part 3 of 3 (PDF – 22MB) 2/8/2017 Exclusivity Determination Memorandum for Morphabond (morphine sulfate) extended-release tablets for NDA 206544, (dated 11/16/16) (PDF – 420KB) 1/25/2017 Decision to waive the requirement for a single, shared system REMS for sodium oxybate oral solution (dated January 17, 2017) (PDF – 1.77MB) 9/27/2016 Recommendation to maintain marijuana in Schedule I of the Controlled Substances Act [Date Range May – June 2015] (PDF – 57MB

Medically Reviewed By: Felicia Eddings, Pharm.D.

Clinical :: Oncology :: Nuclear :: Geriatric :: Regulatory :: Technology :: Consulting

"My passion is helping businesses, small and large, perform at their best." - Felicia Udoji-Eddings, Pharm.D.

Dr. Felicia Udoji-Eddings is the Founder and CEO of The Health Pals Company, a vertically integrated Healthcare System. As an experienced Clinical Pharmacy Leader, Pharmacy Consultant, Healthcare Executive, and Licensed Pharmacy Practitioner with deep backgrounds in Information Technology (IT), Scientific Research, and Business Management. Dr. Udoji-Eddings has a strong track record of exceptional performance in different business environments. A skilled Business Strategist, Dr. Udoji-Eddings has tackled complex problems and helped several organizations refocus their strategy in tough economic times. As a highly motivated and proactive individual, Felicia enjoys working with teams, in various capacities, to facilitate positive outcomes.

View all posts by this author